VIVUS, Inc. (VVUS): Price and Financial Metrics
VVUS Price/Volume Stats
| Current price | $0.47 | 52-week high | $4.75 |
| Prev. close | $0.52 | 52-week low | $0.44 |
| Day low | $0.46 | Volume | 2,026,800 |
| Day high | $0.50 | Avg. volume | 1,441,313 |
| 50-day MA | $1.00 | Dividend yield | N/A |
| 200-day MA | $2.08 | Market Cap | 8.33M |
VVUS Stock Price Chart Interactive Chart >
VIVUS, Inc. (VVUS) Company Bio
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company was founded in 1991 and is based in Mountain View, California.
Latest VVUS News From Around the Web
Below are the latest news stories about Vivus Inc that investors may wish to consider to help them evaluate VVUS as an investment opportunity.
Vivus moves closer to emerging from bankruptcyVivus (VVUS) plummets 26% premarket after completing the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma will take 100% ownership of the company (the “Prepackaged Plan”), ahead of its Chapter 11 filing.The company solicited IEH as the only holder of claims and has received IEH’s voting in favor of... |
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For BankruptcyHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma... |
VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLCVIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020. |
VVUS: Enterprise Valuation UpdateBy John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT Debt Restructuring In May 2013, Vivus, Inc. (NASDAQ:VVUS) closed offerings of $250 million of 4.5% convertible debt that became due in May 2020. The conversion rate of the notes is 6.73038 per $1,000 of face value leaving them well out of the money and unable to convert. Without conversion, the notes remained as debt and |
Vivus files for equity offeringVIVUS (VVUS) has filed a preliminary prospectus for a public offering of stock and warrants of up to ~$186M. Prices, volumes and terms have yet to be determined.Shares down 3% premarket on light volume.... |
VVUS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | -84.28% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 21.97% |
| 2018 | -55.67% |
Continue Researching VVUS
Here are a few links from around the web to help you further your research on Vivus Inc's stock as an investment opportunity:Vivus Inc (VVUS) Stock Price | Nasdaq
Vivus Inc (VVUS) Stock Quote, History and News - Yahoo Finance
Vivus Inc (VVUS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...